Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies
Didier Blaise(Institut Paoli-Calmettes), Anne-Marie Stoppa(Institut Pprime), Jean El Cheikh(Institut Pprime), Norbert Vey(Centre de Recherche en Cancérologie de Marseille), Laure Farnault(Aix-Marseille Université), Sabine Fürst(Institut Pprime), Réda Bouabdallah(Institut Paoli-Calmettes), Patrick Ladaique(Institut Paoli-Calmettes), Catherine Faucher(Institut Paoli-Calmettes), N Marchetti(Institut Paoli-Calmettes)
Cited by 39
Related Papers
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
|Journal of Clinical Oncology|2013|543
Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2016|538
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
|Leukemia|2011|464
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
|The Lancet Haematology|2016|431